by Market Overview:
Cell therapy manufacturing involves the development of cell-based products for clinical applications. These products are associated with the treatment of cancer, neurological disorders, and cardiac conditions. The need for personalized and effective cell therapy is growing widely.
Market key trends:
One of the key trends in the cell therapy manufacturing market is the rise in contract manufacturing. Majority of biopharma companies lack in-house cell and gene therapy manufacturing capabilities and infrastructure. Hence, they rely on contract manufacturing organizations (CMOs) for their clinical and commercial production. CMOs provide services ranging from cell line development, process and analytical development, to final drug product manufacturing and storage. This outsourcing model has boosted the contract manufacturing market for advanced therapy medicinal products.
Earlier, cell therapies were manufactured from a patient’s own cells which involved complex procedures. However, allogenic cell therapies which are developed from standardized and scalable processes are gaining popularity as they can be manufactured in bulk and are cost-effective. This has boosted investments in developing off-the-shelf allogenic therapies for various clinical indications.
The global Cell Therapy Manufacturing Market Size is estimated to be valued at US$ 12.99 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis
Strength: Standardized and scalable manufacturing processes of allogenic cell therapies have made them more affordable and accessible for patients.
Weakness: Limited donor cell availability and rejection risks associated with allogenic therapies.
Opportunity: Large untapped markets for cell therapy in regions like Asia Pacific and Latin America present significant growth opportunities.
Threats: Stringent regulatory norms and high development costs associated with cell therapy products increase uncertainty.
Key Takeaways
The global cell therapy manufacturing market is expected to witness high growth, exhibiting 15% CAGR over the forecast period of 2023 to 2030, due to increasing investments in developing off-the-shelf allogeneic therapies.
Regional analysis: North America dominated the market and is expected to maintain its lead during the forecast period. However, Asia Pacific is anticipated to grow at the fastest pace owing to rising healthcare spending, the growing biotech industry and the presence of emerging economies like China and India providing opportunities for market expansion in the region.
Key players operating in the cell therapy manufacturing market are WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HELIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc. Companies are focusing on scaling up production through partnerships, M&As and expanding manufacturing facilities to cater to the growing demand.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
